Ceritinib ALK inhibitors

Description Results

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

PFS 0.55 [0.42; 0.73] median 16.6 vs. 8.1

OS 0.73 [0.50; 1.07] median NR vs. 26.2

oral ceritinib 750 mg/day (n=189)

vs.

platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 weeks for four cycles followed by maintenance pemetrexed (n=187)

open-label

Sample size: 189/187

Primary endpoint: pfs

FU duration:

Oral LDK378 750 mg once daily (n=-9)

vs.

pemetrexed or docetaxel (n=-9)

Sample size: -9/-9

Primary endpoint: PFS

FU duration:

cediranib 20mg daily to carboplatin/paclitaxel (n=-9)

vs.

(n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

phase II

(n=-9)

vs.

(n=-9)

double-blind

Sample size: -9/-9

Primary endpoint:

FU duration:

phase II/III